CagriSema
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is CagriSema?
Novo Nordisk's investigational fixed-dose pairing of cagrilintide with semaglutide.
In REDEFINE 1 it produced average weight loss of 20.4% by week 68, or 22.7% under the adherent estimand, where semaglutide by itself managed 14.9%. An NDA is filed. Novo had guided to 25%, so the result disappointed against the company's own forecast while still beating semaglutide. That is why write-ups of it swing either way depending on the author.
Read more:
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where CagriSema comes up on this site
On GLP Watchdog, CagriSema comes up in 4 research articles.
Research that discusses it
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers